Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans, leading to clinical candidate ART352-L. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.
View Top Employees from Ankasa (Biotechnology)| Website | https://ankasaregenerativetherapeutics.com/ |
| Employees | 6 (3 on RocketReach) |
| Founded | 2014 |
| Address | 329 Oyster Point Blvd 3rd Floor, South San Francisco, California 94080, US |
| Phone | (858) 750-4739 |
| Industry | Research Services, Business Services General, Biotechnology, Business Services, Therapeutic Devices |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 541714 Companies |
Looking for a particular Ankasa (Biotechnology) employee's phone or email?
Ankasa (Biotechnology) Questions
Jill Helms is the Chief Scientific Officer of Ankasa (Biotechnology).
3 people are employed at Ankasa (Biotechnology).
Ankasa (Biotechnology) is based in South San Francisco, California.
The NAICS codes for Ankasa (Biotechnology) are [54, 54171, 5417, 541, 541714].
The SIC codes for Ankasa (Biotechnology) are [87, 873].
Top Ankasa (Biotechnology) Employees
-
View
Jill Helms
Chief Scientific Officer at Ankasa (Biotechnology)
Portola Valley, California, United States13 -
54
-
ViewAlbert Your
Senior Director, CMC at Ankasa (Biotechnology)
Cupertino, California, United States1
Related Companies
